IMREG-1

01/01/1991 - "IMREG-1 is a promising therapeutic for HIV-infected patients with symptoms of ARC."
01/01/1991 - "On the basis of initial studies of IMREG-1 in patients with AIDS-Related Complex (ARC), a multicenter randomized, double-blind, placebo controlled trial of this agent was carried out. "
07/15/1991 - "Patients with AIDS-related complex experienced fewer adverse events and constitutional symptoms after IMREG-1 treatment. "
01/01/1991 - "Clinical and immunologic observations in patients with AIDS-related complex treated with IMREG-1."
01/01/1991 - "IMREG-1, an immunomodulatory biological therapeutic, was studied in a placebo-controlled, double-blind, six-month trial in 45 anergic patients with AIDS-related complex (ARC) and 4 with Kaposi's sarcoma, which was followed by compassionate IMREG-1 administration to all subjects. "

01/01/1991 - "The IMREG-1 group had significantly less AIDS-defining events compared with the placebo group during the randomized trial (6.9 events per 100 person-years vs 43.7 events per 100 person-years, P = 0.018, relative risk 6.33) and the total observation period. "
01/01/1991 - "The results indicate that patients who received IMREG-1 had a lower risk of progression to frank AIDS than those who received placebo. "
06/01/1990 - "Specifically, IMREG-1 reduced the risk of progression from advanced AIDS-related complex (ARC) based on a randomized double-blinded control trial over a six month period of the laboratory and clinical parameters predictive of a high risk of progression from ARC to AIDS. "
07/15/1991 - "Twelve of forty-eight patients on placebo and 5 of 95 patients on IMREG-1 experienced adverse events (AIDS-defining opportunistic infection or neoplasm, wasting syndrome, HIV-associated encephalopathy, or peripheral sensory neuropathy). "
03/01/1991 - "However, two thymomimetic drugs, isoprinosine and diethyldithiocarbamate, inhibit the development of infections in patients with pre-AIDS in large multicenter trials, and preliminary data from trials with two thymomimetic peptides, thymopentin and ImReg-1, in pre-AIDS patients are encouraging."

01/01/1991 - "IMREG-1, an immunomodulatory biological therapeutic, was studied in a placebo-controlled, double-blind, six-month trial in 45 anergic patients with AIDS-related complex (ARC) and 4 with Kaposi's sarcoma, which was followed by compassionate IMREG-1 administration to all subjects. "

03/01/1991 - "However, two thymomimetic drugs, isoprinosine and diethyldithiocarbamate, inhibit the development of infections in patients with pre-AIDS in large multicenter trials, and preliminary data from trials with two thymomimetic peptides, thymopentin and ImReg-1, in pre-AIDS patients are encouraging."

07/15/1991 - "The slower loss of CD4+ cells and increased size and rate of delayed hypersensitivity responses most likely reflect the effect of IMREG-1 on the immune system. "
07/15/1991 - "In patients receiving IMREG-1, the size and rate of delayed hypersensitivity responses were larger than in the placebo group. "
01/01/1991 - "An immunomodulator, IMREG-1, derived from human leukocyte dialysates exerts a variety of effects on the cell-mediated immune system, including acceleration and amplification of delayed hypersensitivity to recall antigens, modulation of gamma-interferon production in response to antigen, and enhanced expression of the p55 portion of the receptor for interleukin-2 on CD4+ cells. "